Skip to main content
Fig. 2 | BMC Musculoskeletal Disorders

Fig. 2

From: Topical co‐administration of zoledronate with recombinant human bone morphogenetic protein-2 can induce and maintain bone formation in the bone marrow environment

Fig. 2

Representative X-ray images of the left distal femurs of rabbits from each group at 0, 3, and 6 weeks after implantation. In the images, the left side is distal side of femur and the upper side is dorsal side of femur. The radiolucencies at the area of implanted β-TCP columns gradually increased. The radiolucencies of β-TCP columns in groups containing ZOL (i and l) were comparatively more recognizable than in the other groups without ZOL (c and f) at 6 weeks after implantation

Back to article page